FDA approves new drug for PAH
On Dec. 22, the U.S. Food and Drug Administration (FDA) approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH). Read more.
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.